Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD
Shama Naz, Johan Kolmert, Mingxing Yang, Stacey N Reinke, Muhammad Anas Kamleh, Stuart Snowden, Tina Heyder, Bettina Levänen, David J Erle, C Magnus Sköld, Åsa M Wheelock, Craig E Wheelock, Shama Naz, Johan Kolmert, Mingxing Yang, Stacey N Reinke, Muhammad Anas Kamleh, Stuart Snowden, Tina Heyder, Bettina Levänen, David J Erle, C Magnus Sköld, Åsa M Wheelock, Craig E Wheelock
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and a leading cause of mortality and morbidity worldwide. The aim of this study was to investigate the sex dependency of circulating metabolic profiles in COPD.Serum from healthy never-smokers (healthy), smokers with normal lung function (smokers), and smokers with COPD (COPD; Global Initiative for Chronic Obstructive Lung Disease stages I-II/A-B) from the Karolinska COSMIC cohort (n=116) was analysed using our nontargeted liquid chromatography-high resolution mass spectrometry metabolomics platform.Pathway analyses revealed that several altered metabolites are involved in oxidative stress. Supervised multivariate modelling showed significant classification of smokers from COPD (p=2.8×10-7). Sex stratification indicated that the separation was driven by females (p=2.4×10-7) relative to males (p=4.0×10-4). Significantly altered metabolites were confirmed quantitatively using targeted metabolomics. Multivariate modelling of targeted metabolomics data confirmed enhanced metabolic dysregulation in females with COPD (p=3.0×10-3) relative to males (p=0.10). The autotaxin products lysoPA (16:0) and lysoPA (18:2) correlated with lung function (forced expiratory volume in 1 s) in males with COPD (r=0.86; p<0.0001), but not females (r=0.44; p=0.15), potentially related to observed dysregulation of the miR-29 family in the lung.These findings highlight the role of oxidative stress in COPD, and suggest that sex-enhanced dysregulation in oxidative stress, and potentially the autotaxin-lysoPA axis, are associated with disease mechanisms and/or prevalence.
Conflict of interest statement
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
Copyright ©ERS 2017.
Figures
References
- Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765–773.
- Adamko DJ, Nair P, Mayers I, et al. . Metabolomic profiling of asthma and chronic obstructive pulmonary disease: a pilot study differentiating diseases. J Allergy Clin Immunol 2015; 136: 571–580.
- Snoeck-Stroband JB, Lapperre TS, Gosman MME, et al. . Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008; 31: 70–77.
- Han MK, Postma D, Mannino DM, et al. . Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med 2007; 176: 1179–1184.
- Sørheim IC, Johannessen A, Gulsvik A, et al. . Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax 2010; 65: 480–485.
- Camp PG, Coxson HO, Levy RD, et al. . Sex differences in emphysema and airway disease in smokers. Chest 2009; 136: 1480–1488.
- Eisner MD, Anthonisen N, Coultas D, et al. . An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693–718.
- To T, Zhu J, Larsen K, et al. . Progression from asthma to chronic obstructive pulmonary disease. Is air pollution a risk factor? Am J Respir Crit Care Med 2016; 194: 429–438.
- Kurt OK, Zhang J, Pinkerton KE. Pulmonary health effects of air pollution. Curr Opin Pulm Med 2016; 22: 138–143.
- Valko M, Leibfritz D, Moncol J, et al. . Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44–84.
- Vestbo J, Hurd SS, Agustí AG, et al. . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
- Kohler M, Sandberg A, Kjellqvist S, et al. . Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131: 743–751.
- Forsslund H, Mikko M, Karimi R, et al. . Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction. Chest 2014; 145: 711–722.
- Karimi R, Tornling G, Forsslund H, et al. . Lung density on high resolution computer tomography (HRCT) reflects degree of inflammation in smokers. Respir Res 2014; 15: 23.
- Balgoma D, Yang M, Sjödin M, et al. . Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD. Eur Respir J 2016; 47: 1645–1656.
- Reinke SN, Gallart-Ayala H, Gomez C, et al. . Metabolomics analysis identifies different metabotypes of asthma severity. Eur Respir J 2017; 49: 1601740.
- Wishart DS, Jewison T, Guo AC, et al. . HMDB 3.0 – the Human Metabolome Database in 2013. Nucleic Acids Res 2013; 41: D801–D807.
- Kamleh MA, Snowden SG, Grapov D, et al. . LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment. J Proteome Res 2015; 14: 557–566.
- Bijlsma S, Bobeldijk I, Verheij ER, et al. . Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem 2006; 78: 567–574.
- Dunn WB, Wilson ID, Nicholls AW, et al. . The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis 2012; 4: 2249–2264.
- Gromski PS, Xu Y, Kotze HL, et al. . Influence of missing values substitutes on multivariate analysis of metabolomics data. Metabolites 2014; 4: 433–452.
- Wheelock ÅM, Wheelock CE. Trials and tribulations of ’omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol Biosyst 2013; 9: 2589–2596.
- Wiklund S, Johansson E, Sjöström L, et al. . Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008; 80: 115–122.
- Kamburov A, Cavill R, Ebbels TM, et al. . Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 2011; 27: 2917–2918.
- Molina-Pinelo S, Pastor MD, Suarez R, et al. . MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. Eur Respir J 2014; 43: 1740–1749.
- Osei ET, Florez-Sampedro L, Timens W, et al. . Unravelling the complexity of COPD by microRNAs: it's a small world after all. Eur Respir J 2015; 46: 807–818.
- Conickx G, Mestdagh P, Avila Cobos F, et al. . MicroRNA profiling reveals a role for microRNA-218-5p in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 195: 43–56.
- Benipal B, Feinstein SI, Chatterjee S, et al. . Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia. Redox Biol 2015; 4: 321–327.
- Ben Moussa S, Rouatbi S, Saad HB. Incapacity, handicap, and oxidative stress markers of male smokers with and without COPD. Respir Care 2016; 61: 668–679.
- Conlon TM, Bartel J, Ballweg K, et al. . Metabolomics screening identifies reduced l-carnitine to be associated with progressive emphysema. Clin Sci 2016; 130: 273–287.
- Lommatzsch M, Cicko S, Müller T, et al. . Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 928–934.
- Tam A, Churg A, Wright JL, et al. . Sex differences in airway remodeling in a mouse model of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016; 193: 825–834.
- Aydin M, Altintas N, Cem Mutlu L, et al. . Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD. Clin Respir J 2017; 11: 318–327.
- Ruzsics I, Nagy L, Keki S, et al. . l-Arginine pathway in COPD patients with acute exacerbation: a new potential biomarker. COPD 2016; 13: 139–145.
- Scott JA, Duongh M, Young AW, et al. . Asymmetric dimethylarginine in chronic obstructive pulmonary disease (ADMA in COPD). Int J Mol Sci 2014; 15: 6062–6071.
- Scott JA, North ML, Rafii M, et al. . Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med 2011; 184: 779–785.
- Ricciardolo FL, Caramori G, Ito K, et al. . Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J Allergy Clin Immunol 2005; 116: 1028–1035.
- van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007; 46: 145–160.
- Van der Aar E, Fagard L, Desrivot J, et al. . Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD. Eur Respir J 2015; 46: Suppl. 59, OA484.
- Solberg OD, Ostrin EJ, Love MI, et al. . Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med 2012; 186: 965–974.
- Cushing L, Kuang P, Lü J. The role of miR-29 in pulmonary fibrosis. Biochem Cell Biol 2015; 93: 109–118.
- Jiang H, Zhang G, Wu JH, et al. . Diverse roles of miR-29 in cancer (review). Oncol Rep 2014; 31: 1509–1516.
- Wu DW, Hsu NY, Wang YC, et al. . c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene 2015; 34: 2072–2082.
- Nowak-Machen M, Lange M, Exley M, et al. . Lysophosphatidic acid generation by pulmonary NKT cell ENPP-2/autotaxin exacerbates hyperoxic lung injury. Purinergic Signal 2015; 11: 455–461.
- Chu X, Wei X, Lu S, et al. . Autotaxin-LPA receptor axis in the pathogenesis of lung diseases. Int J Clin Exp Med 2015; 8: 17117–17122.
- Park GY, Lee YG, Berdyshev E, et al. . Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med 2013; 188: 928–940.
- Ackerman SJ, Park GY, Christman JW, et al. . Polyunsaturated lysophosphatidic acid as a potential asthma biomarker. Biomark Med 2016; 10: 123–135.
- Pleli T, Martin D, Kronenberger B, et al. . Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis – a prospective cohort study. PLoS One 2014; 9: e103532.
- Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol 2014; 192: 851–857.
- Katoh A, Ikeda H, Murohara T, et al. . Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation. Circulation 1998; 98: 2891–2898.
- Maskrey BH, Rushworth GF, Law MH, et al. . 12-hydroxyeicosatetraenoic acid is associated with variability in aspirin-induced platelet inhibition. J Inflamm 2014; 11: 33.
- Keune WJ, Hausmann J, Bolier R, et al. . Steroid binding to autotaxin links bile salts and lysophosphatidic acid signalling. Nat Commun 2016; 7: 11248.
Source: PubMed